(Q44073507)

29 November 2017

title

Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up (English)

1 reference

29 November 2017

G Bresci

1

1 reference

29 November 2017

G Parisi

series ordinal

2

1 reference

29 November 2017

M Bertoni

series ordinal

3

1 reference

29 November 2017

A Capria

series ordinal

4

1 reference

29 November 2017

publication date

1 June 2002

1 reference

Digestive and Liver Disease

29 November 2017

published in

1 reference

29 November 2017

volume

34

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

419-423

1 reference

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

The incidence and prevalence of inflammatory bowel disease in North Tees Health District

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Ulcerative colitis and Crohn's disease on the Faroe Islands 1964-83. A retrospective epidemiological survey

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Chronic ulcerative colitis: incidence and prevalence in a community

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Ulcerative proctitis in central Sweden 1965-1983. A population-based epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Is maintenance therapy always necessary for patients with ulcerative colitis in remission?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Clinical patterns, natural history, and progression of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Olsalazine in maintenance of clinical remission in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980039-1

7 January 2021

10.1016/S1590-8658(02)80039-1

Identifiers

DOI

1 reference

29 November 2017

1 reference